Browsing: rare

The University of Texas at Arlington is creating a new approach to its graduate program in which doctoral students will train to become experts in a single rare disease while moving their research from the lab to real-world diagnosis, clinical trials and treatment

LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin disease, has entered into an agreement to acquire worldwide rights to dersimelagon from Japan-based Tanabe Pharma. Dersimelagon is an oral, once-daily small MC1R agonist being developed for erythropoietic protoporphyria (EPP) and X-linked proto-porphyria (XLP)